💉 GLP-1 Medications: Indication of Use & Safety Information
Indication for Use
GLP-1 receptor agonists (such as Semaglutide and Tirzepatide) are FDA-approved for the treatment of type 2 diabetes and/or chronic weight management in adults with a BMI ≥30 (or ≥27 with a weight-related condition). These medications help regulate blood sugar, control appetite, and support sustainable weight loss when combined with lifestyle changes.
✅ Potential Benefits
Significant weight loss over time
Reduced appetite and cravings
Improved blood sugar control
Lower risk of cardiovascular events in certain patients
Enhanced metabolic function
⚠️ Common Side Effects
Most side effects are dose-dependent and often decrease over time:
Nausea, vomiting, constipation, or diarrhea
Fatigue or dizziness
Mild abdominal pain or bloating
Loss of appetite or taste changes
Rare but serious risks include:
Pancreatitis
Gallbladder issues (e.g., gallstones)
Thyroid C-cell tumors (seen in animal studies)
Low blood sugar (especially if on other glucose-lowering medications)
🚫 Contraindications
GLP-1 medications are not recommended for individuals with:
Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Active gallbladder disease
History of pancreatitis
Severe gastrointestinal disease (e.g., gastroparesis)
Current or planned pregnancy and breastfeeding
📅 Follow-Up Requirements
To ensure safety and effectiveness, we require:
Completion of the medical intake form and lab work (as applicable)
An initial consultation with a licensed provider
Monthly check-ins or refill evaluations to monitor progress, side effects, and medication adjustments
Immediate reporting of severe or unusual symptoms (e.g., persistent vomiting, sharp abdominal pain, signs of dehydration)
Your provider may adjust your dose or recommend stopping therapy if risks outweigh benefits.